WELCOME TO THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER
Thank you for supporting BASL2020. Presentations from the Virtual Annual Meeting are now available through the OnAir events portal using your registration log on.
BASL2020 VIRTUAL ANNUAL MEETING
21st - 24TH September 2021 - PROVISIONAL DATE
Thank you to our members and to the liver community who supported BASL2020. Presentations from the Virtual annual meeting are now available to view through the OnAir meeting portal. Registrants should use their registration log on details to access. Provisional dates for BASL2021 are Tuesday 21st - Friday 24th September – to include BLTG & BLNA - these dates will be confirmed as soon as possible.
BASL VIRTUAL ANNUAL MEETING
BASL AND BASL SUB-GROUPS
The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
British Liver Nurses' Association is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development. The BLTG will foster close relationships with BTS (British Transplant Society) and LICAGE (Liver Intensive Care Group of Europe) and will build on the role of the UK and Ireland Annual Meeting by delivering structure and authority to the group.
Is a professional pharmacy organisation aiming to develop knowledge and understanding of liver disorders including viral hepatitis, in order to improve the quality of patient care, through medicines optimisation, collaborative and multi-disciplinary working and promoting patient-focused research.
HCC UK is a multi-disciplinary organisation aiming to promote collaboration in research, education and clinical service development for primary liver cancer. We bring together leading oncologists, liver surgeons, hepatologists, basic scientists, radiologists, pathologists and specialist nurses to lead improvement in the quality of patient care.
BASL President's BlogRead more
The 2020 Nobel Prize in Physiology or Medicine is awarded jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. Labelled a Cinderella story of medicine, investigations for causes and prevention of ‘post-transfusion hepatitis’ started with Harvey Alter an aspiring haematologist who collaborated with Baruch Blumberg leading to the discovery of hepatitis B; Harvey Alter was the second author in the original article (view > here) and the first author of the next describing the characteristics of the ‘Australia antigen’ (view > here).
Harvey Alter later observed that only 20% of transfusion hepatitis was explained by the hepatitis B virus and carried on to demonstrate the transmissibility of the ‘non-A, non-B hepatitis virus ’ in chimpanzees. Michael Haughton led the direct molecular cloning of HCV (view > here). While Blumberg won the Nobel Prize way back in 1976, Alter together with Houghton in 2000 and Charles Rice in 2016 (for his seminal work on HCV replicon system) received the Lasker Award (hailed as a pre-Nobel award).
Following the Lasker Award, Alter said that ‘I am perhaps the thread that links these events, but the story is a fabric woven by many collaborators who played essential parts and by the conducive environment of the National Institutes of Health (NIH) intramural program that has nurtured these clinical investigations...My gratitude is without bounds’. He also wrote about the discovery of Australia antigen, a serendipity (view > here).
Houghton’s response to the Nobel award was that ‘We thought it would be solved quickly, but it actually took seven years to find’.
Rice reminisced that ‘Manufacturers are now attempting to lower the price, in part by granting production rights in poorer countries. I would have been much happier had it been more rapid.’ Rice also told the interviewer that the WHO was unlikely to be able to eradicate the virus by 2030, in part because a broadly effective and widely available vaccine was still years away.
An essay on the history of Hepatitis C by Harvey Alter, was recently published online in the AASLD Journal Clinical Liver Disease; Download History Of HCV - BLOG 2020.pdf
Frontline Gastroenterology: Call for Trainee Associate EditorsRead more
IQILS accreditation – quality lead roleRead more
The Royal College of Physicians’ Accreditation Unit is seeking to appoint a quality lead to take responsibility for the level one submissions of services working towards full accreditation and supporting services to level 2. The post holder will represent IQILS and support the development of the programme and increase awareness and engagement among Liver services.
This is an exciting and varied role suitable for a consultant hepatologist. The time commitment is 0.5 PA per week. The role description can be found on the IQILS website: https://www.iqils.org/CMS/AllNews.aspx
If you are interested in this role, please send your CV and a supporting statement of no more than 2 pages outlining how you meet the person specification to email@example.com by the closing date.
Please contact the IQILS manager, Madeline Bano at firstname.lastname@example.org if you have any questions or would like an informal discussion about the role.
Applications will close at midnight on Sunday 8 November 2020. Interviews will be held in the morning of Thursday 19 November.
The Royal College of Physicians (RCP) believes that equality of opportunity is fundamental in whatever way individuals become involved with the RCP, whether as physicians, physicians-in-training or staff. It welcomes and actively seeks to recruit people to its activities regardless of race, religion, ethnic origin, disability, age, gender and sexual orientation. The RCP aims to reflect the diversity of its members in all its committee, senior roles and staff.
Patients with cirrhosis at increased risk of death from COVID-19, study findsRead more
An international study led by researchers at Oxford University Hospitals NHS Foundation Trust has shown that patients with cirrhosis are at increased risk of dying as a result of COVID-19.
The study, published in the Journal of Hepatology, found that mortality from COVID-19 was particularly high among patients with more advanced cirrhosis (called Childs-Pugh B or C cirrhosis) and those with alcohol-related liver disease.
The study was a collaboration between scientists at the Oxford Liver Unit, based at Oxford’s John Radcliffe Hospital, and colleagues at the University of North Carolina (USA), and was supported by the European Association for the Study of the Liver (EASL)
The paper presented data on over 1,300 patients from 29 different countries and compared COVID-19 outcomes between patients with and without liver disease.
“Our study confirms that severity of liver disease is closely associated with poor outcomes from COVID-19, with cirrhosis patients being at significantly increased risk of death,” said Dr Thomas Marjot, who leads the study alongside Professor Eleanor Barnes of the University of Oxford’s Nuffield Department of Medicine.
“Given the huge global burden of cirrhosis, with an estimated 112 million people affected, and the resurgence of the virus in many areas of the world these findings have far-reaching implications for how we manage patients with liver disease during the pandemic. This includes the need to consider enhanced protection and social distancing for patients with advanced cirrhosis,” Dr Marjot explained.
The study found that mortality among patients with cirrhosis was 32%, compared with 8% in those without. However, the risk of mortality increased in those with more advanced forms of cirrhosis, rising as high as 51% in those in the most severe category. Other risk factors for death included advancing age and alcohol-related liver disease.
The majority of deaths in cirrhosis patients (71%) were from respiratory failure caused by COVID-19. The virus also seemed to cause a deterioration in liver function, with patients developing complications such as ascites or encephalopathy even in the absence of typical respiratory symptoms of COVID-19.
This work follows a recent publication from the same group in The Lancet Gastroenterology & Hepatology which showed that liver transplant recipients did not appear to be at increased risk of death from the virus.
Dr Andrew Moon at The University of North Carolina said: “This study nicely compliments our findings in patients with prior liver transplantation. In contrast to the presence of advanced cirrhosis, having a liver transplantation was not associated with increased risk of death from COVID-19. This suggests that we should aim to continue liver transplant services during the pandemic wherever possible.”
Professor Thomas Berg, EASL Vice-Secretary General and Head of the Division of Hepatology at Leipzig University Medical Centre in Germany, said: “The findings from this large registry study are very relevant to clinicians and patients worldwide, as we continue to optimise liver disease management during the pandemic.
“These results are timely and reinforce the recommendations made in the joint Position Papers by EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published in JHEP Reports, which offer guidance on how to approach patients with different types and stages of liver disease.”
Roy Probert, Senior Communications Manager
Mobile: 07341 115585
The effect of lockdown on patients with alcohol-related liver disease: a national service evaluationRead more
Many people have been consuming more alcohol during lockdown, especially those with hazardous or harmful drinking behaviour. Anecdotal observations suggest an increase in the number and severity of admissions of patients with alcohol-related liver disease (ArLD) since lockdown was implemented with more patients presenting with advanced disease including variceal haemorrhage and alcoholic hepatitis. The ArLD Special Interest Group aims to perform a systematic national service evaluation of ArLD hospital episodes to determine whether the number of ArLD patients and the severity of their disease is different post-lockdown compared to a similar period in 2019. Working in collaboration with Public Health colleagues, this information will be combined with a national dataset to help us understand the effect of lockdown on our vulnerable patient group and to plan alcohol services at a local and national level.
We need your help to contribute data from your Trust. We are using a validated Excel-based tool to identify eligible patients and a simple Excel data collection tool. An evaluation lead and any other assistant (e.g. specialty trainee) at each participating centre will be recognised as co-authors in any publications that arise from this evaluation.
To register your interest in participating in this national service evaluation and to receive further details, please email me at email@example.com .
Thank you for your support,
Dr Ashwin Dhanda, BASL ArLD SIG lead
The BLTG Committee are sorry that they have had to postpone the upcoming BLTG webinar: "Onwards and upwards - lessons learned from the first phase of the coronavirus pandemic".
This decision has not been taken lightly and reflects the evolving situation with COVID-19.
A save the date for January will be added shortly and more details will follow when available.
The next meeting of the CCA-UK SIG will take place as a webinar via Zoom on:
Date: Monday 14th December
Time: 17:30 - 19:30
Free to attend and all welcome.
View a programme here > Download BASL CCA-UK SIG Webinar Prog 14 Dec 2020 Website 3.pdf
Download a flyer to share with colleagues - Download CCA-UK Webinar Flyer 14 Dec 2020.pdf
Please read the BASL Events Data Protection Disclaimer below before registering:
REGISTER through Zoom by clicking > here
Should you have any questions, or any comments or concerns over your data please contact firstname.lastname@example.org .
Thank you to:
'This webinar is supported by Incyte. They have had no influence or input into the programme, agenda or content of the meeting’.
The BLNA Committee are sorry that they have had to postpone the upcoming BLNA webinar.
This decision has not been taken lightly and reflects the evolving situation with COVID-19.
A save the date for February will be added shortly and more details will follow when available.
Should you have any questions, please contact email@example.com .
07/01/21 - 08/01/21
The RCP Annual Conference Medicine 2020 has been delayed until 7 -8 January 2021.
Venue - The ICC, Birmingham.
Bringing together speakers at the forefront of improving patient care, Medicine 2020 will provide an essential national update for physicians from all career grades and specialties. Exploring ground-breaking medical developments, we’ll focus on how to deliver world-class healthcare.
More information can be found on the RCP website here > https://www.rcplondon.ac.uk/events/medicine-2020-rcp-annual-conference
SAVE THE DATE
The BASL School of Hepatology will run as a series of monthly webinars in 2021 starting on Wednesday 20th January from 19:00 - 20:00.
Topics are being worked on and future dates are being confirmed.
The webinars will be open to BASL Members.
Look out for future announcements on the website and on Twitter @BASLedu.
Should you have any questions, please contact firstname.lastname@example.org .